Icon
+91 94997 68112
Login Register

Triumeq - (EQ 600mg/50mg/300mg Base; Tablet)

Abacavir Sulfate, Dolutegravir and Lamivudine VIIV Healthcare
EQ 600mg/50mg/300mg Base; Tablet
More Than $1000 mn
Less Than 5
More Than 5
More Than 5
Less Than 5
None None
TRIUMEQ is a combination of dolutegravir (integrase strand transfer inhibitor [INSTI]), abacavir, and lamivudine (both nucleoside analogue reverse transcriptase inhibitors) indicated for the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 10 kg.
Yes
*****, ***** (******), ******, ***** *** ** *****'* ***** * **** ** ** ****** '*** *** **** *********. *** *** ****. ** ****** **** **** **** ****** ** *** ****. *****, **** ******* **** *****, ***** *** ***** ** ********** *** *** *****. ********* ** ****-*** *** ******, ******** ****** ** ******* ****** ** *** ****. **, **** ** *** ******** *** ****** ******* ****** ****. ****** **** ******* **** ****-*** ** ******* ***** *** *** ********* ********. ***** ** *** *, **** **** ****** ******* **** *****. ** **** **, **** **** ****** ******* **** ****** **** *********** *****. *** ********* ** **** ****** (** *****'*) *** *********** ** ****** **** ** *** ****. ******* ********** **** **** **** *** ******* ****** **** ******* ** ** *****'*.
Triumeq Patent 1 Patent 2
***** *** ********* *******
***** ******* *******
***** *** ********* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** \ ** *** *, **** ******* **** ***** *** **** (***** ******)
***** *** \ ** *** **, **** ******* **** ***** *** **** (***** ******)
***** *** \ ** *** **, **** ******* **** ***** *** **** (***** ******)
  1. *** **, **** : ***** ******** **** ********** ***** **'* **** ** ****** ** ******* '***
  2. *** *, **** : ***** ******** **** ********** ***** **'* **** ** ****** ** ******* '***
  3. *** *, **** : ***** ******** **** ********** ***** **'* **** ** ****** ** ******* '***
  4. *** *, **** : ** *****'* ******** **** ********** ***** **'* **** ** ****** ** ******* '***
  5. *** *, **** : **** ********** ***** * **** ******* ***** ** ****** '***
  6. *** **, **** : **** ********** ***** * **** ******* ******, ***** *** ***** ** ****** '***
  7. *** **, **** : **** ********** ***** * **** ******* ** *****'* ** ****** '***
  8. *** **, **** : *****’* ************* *** ******** *** ********** *** **************** ** *** ’*** ****** *** *********.
  9. *** *, **** : **** ******* **** *****, ***** *** ***** ** ********** *** *** *****.
  10. *** *, **** : *****://***.**********.***.***/**********_****/*********/****/*****************_***.*** ********* ******** *** ****** ****
  11. *** *, **** : **** ******* **** ** *****'* (****** ****), ***** *** ***** ** ********** *** *** *****.
  12. *** *, **** : **** ********** ******* **** *****
  13. *** **, **** : **** ********** ******* **** ******
  14. *** *, **** : **** ******* **** ****** , ***** *** ***** ** ********** *** *** *****.
  15. *** *, **** : **** ******* **** *****, ***** *** ***** ** ********** *** *** *****.
  16. *** **, **** : ********* ******** ******** *** *** *** *********. ** ****** **** ***** * **** ***.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.